Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could chemo before surgery beat cancer better?

NCT ID NCT07492225

Disease control Sponsor: Changhai Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments for a rare type of urinary tract cancer. One group gets chemotherapy before surgery, the other has surgery alone. The goal is to see if chemo helps shrink the tumor and improve long-term outcomes. About 120 adults with high-risk, non-spread cancer are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed high-risk upper tract urothelial carcinoma (UTUC). 2. Clinically non-metastatic UTUC (N≤1, M0) based on imaging (CT/MRI). 3. Planned for radical nephroureterectomy (RNU). 4. ECOG performance status of 0 or 1. 5. Sufficient renal function (GFR ≥45 mL/min) and able to tolerate chemotherapy with cisplatin. 6. Age ≥18 years. 7. Informed consent signed. Exclusion Criteria: 1. Imaging shows ≥N2 disease or metastatic disease (M1). 2. History of invasive or lymph node-positive UTUC or invasive disease in the contralateral upper tract in the last 2 years. 3. Single kidney or contraindication to cisplatin. 4. Currently participating in other interventional clinical trials. 5. History of non-urothelial malignancies (except treated skin basal cell carcinoma or cervical carcinoma in situ). 6. Pregnant or breastfeeding women. 7. Any other medical condition deemed inappropriate by the treating physician.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neoadjuvant therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma ureter transitional cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoadjuvant therapy Upper urinary tract urothelial carcinoma Urothelial carcinoma ureter

Contacts and locations

Locations

  • Changhai Hospital

    Shanghai, Shanghai Municipality, 200090, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.